IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-1-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMM-1-104 overview
IMM-1-104 is under development for the treatment of solid tumor, pancreatic ductal adenocarcinoma, non-small cell lung cancer, lung adenocarcinoma, cholangiocarcinoma, metastatic colorectal cancer and NRAS mutant metastatic melanoma. It is administered through oral route. The drug candidate acts by targeting mitogen activated protein kinase (MEK) and kinase suppressor of RAS (KSR). It is developed based on Immuneering artificial intelligence (AI) enabled disease cancelling technology (DCT).
Immuneering overview
Immuneering is a biopharmaceutical company that discovers and develops oncologic and neurologic drugs. The company’s pipeline products include IMM-1-104 and IMM-6-415. Its IMM-1-104 is a dual inhibitor of mitogen-activated protein kinase (MEK) to restrain the pathway that reduces the growth of tumors. Immuneering’s IMM-6-415 candidate treats solid tumors. The company offers drug discovery services by leveraging artificial intelligence. It provides bioinformatics and computational biology services to pharmaceutical and biotechnology companies. The company operates in Massachusetts, New York and California. Immuneering is headquartered in Boston, Massachusetts, the US.
For a complete picture of IMM-1-104’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
